Literature DB >> 27026768

Massive Pulmonary Embolism in a Patient with Heparin Induced Thrombocytopenia: Successful Treatment with Dabigatran.

Haci Ahmet Bircan1, Emine Guchan Alanoglu2.   

Abstract

Heparin induced thrombocytopenia (HIT) is a rare, potentially fatal, immune-mediated complication of heparin therapy, associated with thrombosis and thrombocytopenia. In this study, a successful dabigatran administration in a case with massive pulmonary thromboembolism (mPTE) and HIT is presented. 57 years-old female, who was receiving low molecular weight heparin (LMWH) (0.4 mL once a daily, S.C. for 11 days) due to total knee replacement, was referred to our clinic with the hypotension and syncope attacks. Her echocardiography and pulmonary CT angiography findings were consistent with mPTE. We detected a serious decrease in her platelet count highly suggestive for HIT (plt: 54×10(3)/µL). LMWH was discontinued and dabigatran was started (150 mg twice daily). After platelet count increased over 150×10(3)/μL, dabigatran was switched to warfarin. Since heparin is widely used in medicine, all physicians need to be aware of this life threatening complication of heparin. Replacing heparin with an alternative anticoagulant such as dabigatran may become a life-saving strategy especially in case of HIT complicated with mPTE.

Entities:  

Keywords:  Dabigatran; heparin; low molecular weight heparin; new oral anticoagulants; pulmonary embolism

Year:  2016        PMID: 27026768      PMCID: PMC4792501          DOI: 10.5152/eurasianjmed.2015.95

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  11 in total

Review 1.  Heparin-induced thrombocytopenia.

Authors:  Mark E Comunale; Elizabeth M Van Cott
Journal:  Int Anesthesiol Clin       Date:  2004

Review 2.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Heparin-induced thrombocytopenia: an overview.

Authors:  J G Kelton
Journal:  Blood Rev       Date:  2002-03       Impact factor: 8.250

4.  [Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate].

Authors:  S Meddahi; M M Samama
Journal:  J Mal Vasc       Date:  2011-01-15

5.  [Fondaparinux treatment in heparin induced thrombocytopenia:a case report].

Authors:  Savaş Ozsu; Ahmet Korkmaz; Yilmaz Bülbül; Funda Oztuna; Tevfik Ozlü
Journal:  Tuberk Toraks       Date:  2011

Review 6.  Heparin-induced thrombocytopenia in critically ill patients.

Authors:  Theodore E Warkentin
Journal:  Semin Thromb Hemost       Date:  2015-01-15       Impact factor: 4.180

Review 7.  The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy.

Authors:  Kathryn Hassell
Journal:  Chest       Date:  2005-02       Impact factor: 9.410

8.  Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Sebastian Schellong; Henry Eriksson; David Baanstra; Anne Mathilde Kvamme; Jeffrey Friedman; Patrick Mismetti; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

9.  An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients.

Authors:  Theodore E Warkentin; Robin S Roberts; Jack Hirsh; John G Kelton
Journal:  Arch Intern Med       Date:  2003-11-10

Review 10.  Laboratory diagnosis of immune heparin-induced thrombocytopenia.

Authors:  Theodore E Warkentin; Nancy M Heddle
Journal:  Curr Hematol Rep       Date:  2003-03
View more
  4 in total

Review 1.  Drug-associated thrombocytopenia.

Authors:  Tamam Bakchoul; Irene Marini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Emerging Role of Direct Oral Anticoagulants in the Management of Heparin-Induced Thrombocytopenia.

Authors:  Phu Ngoc Tran; Minh-Ha Tran
Journal:  Clin Appl Thromb Hemost       Date:  2017-03-06       Impact factor: 2.389

3.  Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay.

Authors:  Preethi Ramachandran; Fady Farag; Rewais Morcus; Vladimir Gotlieb
Journal:  Am J Case Rep       Date:  2019-03-09

Review 4.  Dabigatran approaching the realm of heparin-induced thrombocytopenia.

Authors:  Patricia J Ho; Juan A Siordia
Journal:  Blood Res       Date:  2016-06-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.